Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  TEL AVIV STOCK EXCHANGE  >  Teva Pharmaceutical Industries Limited    TEVA   IL0006290147

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Teva Asks FDA Not to Approve New MS Drugs Till Advisers Evaluate Safety

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/09/2013 | 09:09pm CEST
   By Peter Loftus 
 

Teva Pharmaceutical Industries Ltd. (>> Teva Pharmaceutical Industries Ltd (ADR)), which sells the blockbuster multiple-sclerosis drug Copaxone, has asked the U.S. Food and Drug Administration not to approve any new MS drugs until their safety risks have been evaluated by outside advisers.

Teva's petition is aimed at Biogen Idec Inc. (>> Biogen Idec Inc.), which expects an FDA decision by late March on Biogen's application to market a new MS treatment, known as BG-12, an orally administered pill that analysts expect will be a formidable competitor to the injected Copaxone.

In a Dec. 31 citizen petition to the FDA, Teva asked the agency not to approve any new MS drugs until the agency refers them to an advisory committee for evaluation. Advisory committees sometimes review new drug applications to provide guidance to the agency.

Teva said it was important for the agency to hear outside advisers' evaluations of any safety risks, in light of risks that have emerged after MS treatments were approved in recent years, including Biogen's own Tysabri MS treatment. Tysabri was removed from the market soon after its 2004 introduction after some recipients experienced a serious brain infection, and reintroduced in 2006 with a patient-monitoring plan.

Teva said in its petition that BG-12 "may be associated with other serious safety risks" including the potential risk for kidney-related problems.

Teva cited a publicly accessible website containing animal toxicology data suggesting that kidney changes were seen in animals after they received BG-12's active ingredient, dimethyl fumarate, in studies. The website stated that the relevance of these findings to humans isn't known, according to the Teva petition.

Biogen spokeswoman Kate Niazi-Sai said the company is confident in the clinical data supporting BG-12's safety and efficacy, and the regulatory review appears to be on track.

Results of a late-stage clinical trial of BG-12 published last year in the New England Journal of Medicine showed the incidence of kidney-related adverse events was similar between those receiving BG-12 and those on a placebo. There were no cases of kidney failure classified by researchers as serious adverse events, according to the article.

RBC Capital Markets analyst Shibani Malhotra, who reported the Teva citizen petition in a research note earlier Wednesday, said it may not pose a big obstacle for BG-12's approval because a similar drug has been available as a psoriasis treatment in Europe, and serious safety issues haven't emerged.

RBC analyst Michael Yee said he still expects the FDA to approve BG-12 by the targeted action date in late March.

On Monday at the J.P. Morgan Healthcare conference in San Francisco, Biogen Chief Executive George Scangos defended the experimental MS pill. He acknowledged there has been some chatter about BG-12 safety, but chalked this up to competitors marketing against the product.

"We're very confident in the safety," he said. "I kind of take it as a compliment that the competition is worried about BG-12."

Teva spokeswoman Denise Bradley said the petition was intended to bring to light important points "to protect the safety of patients." Teva wants to ensure "that appropriate safeguards are implemented to maintain an acceptable risk-benefit profile" for any new MS drug, she said.

FDA spokeswoman Sandy Walsh said the agency will review the petition.

--Jon Kamp contributed to this article.

-Write to Peter Loftus at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on TEVA PHARMACEUTICAL INDUST
03:03p TEVA PHARMACEUTICAL INDUSTRIES : Announces Planned Departure of Eyal Desheh, Gro..
02:01p TEVA PHARMACEUTICAL INDUSTRIES LIMIT : Today's Research Reports on Stocks to Wat..
01:32p TEVA PHARMACEUTICAL INDUSTRIES LTD ( : TEVA) To Restart Production At Rimsa Plan..
04/25 TEVA PHARMACEUTICAL INDUSTRIES : CFO Eyal Desheh to step down
04/24 TEVA PHARMACEUTICAL INDUSTRIES : launches asthma product with generic version
04/24 TEVA PHARMACEUTICAL INDUSTRIES : Releases AirDuo RespiClick plus Generic for Ast..
04/22 TEVA PHARMACEUTICAL INDUSTRIES : simultaneously launches AirDuo RespiClick and i..
04/21 TEVA PHARMACEUTICAL INDUSTRIES LTD ( : TEVA) Asthma Inhaler To Compete With Glax..
04/21 Teva's new asthma inhaler poses first competition for GSK's Advair
04/20 TEVA PHARMACEUTICAL INDUSTRIES : Patent Issued for Biomarkers Predictive for Cli..
More news
Sector news : Pharmaceuticals - NEC
04:59p New GlaxoSmithKline CEO wants fewer, bigger new drug launches
03:42pDJGLAXOSMITHKLINE : Glaxo's New Boss Emma Walmsley Seeks Sharper R&D Edge--Update
02:00pDJGLAXOSMITHKLINE : Net Income Boosted by Strong Sales, Weak Pound
04/25DJSHIRE : Files 8K - Other Events
04/25DJSHIRE : Files 8K - Changes To Articles
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
09:17a Fresenius Shows Biotech How To Get The Deals Done
08:12a Teva mulling sale of cancer portfolio to reduce debt; shares up 1% premarket
04/25 TEVA PHARMACEUTICAL : Negative In 2015, And Still Negative In 2017
04/25 Teva finance chief to depart for likely Chairmanship at consumer credit firm
04/25 APRIL BUYS : The 14 Stocks Added To My Fund
Advertisement
Financials ($)
Sales 2017 23 456 M
EBIT 2017 7 071 M
Net income 2017 4 011 M
Debt 2017 25 854 M
Yield 2017 3,92%
P/E ratio 2017 7,79
P/E ratio 2018 7,54
EV / Sales 2017 2,43x
EV / Sales 2018 2,25x
Capitalization 31 041 M
More Financials
Chart TEVA PHARMACEUTICAL INDUST
Duration : Period :
Teva Pharmaceutical Indust Technical Analysis Chart | TEVA | IL0006290147 | 4-Traders
Full-screen chart
Technical analysis trends TEVA PHARMACEUTIC...
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 37,5 $
Spread / Average Target 22%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Yitzhak Peterburg President & Chief Executive Officer
Sol J. Barer Chairman
Carlo de Notaristefani President & CEO-Global Operations
Eyal Desheh Chief Financial Officer & Group Executive VP
Michael R. Hayden President-Global Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
TEVA PHARMACEUTICAL IN..-17.79%31 041
JOHNSON & JOHNSON7.13%334 605
ROCHE HOLDING LTD.10.49%223 016
PFIZER INC.3.88%201 045
NOVARTIS AG2.16%199 772
MERCK & CO., INC.5.83%170 797
More Results